Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells

FASEB Journal

Volumn 26, Issue 2, 2012, Pages 788-798

  Salani, Barbara ^a   Maffioli, Sara ^a   Hamoudane, Meriem ^a,b   Parodi, Alessia ^a   Ravera, Silvia ^a   Passalacqua, Mario ^a   Alama, Angela ^c   Nhiri, Mohamed ^b   Cordera, Renzo ^a   Maggi, Davide ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b ABDELMALEK ESSAADI UNIVERSITY   (Morocco)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

AKT; FOXO3a; NSCLC; OCT1

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CAVEOLIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; OCTAMER TRANSCRIPTION FACTOR 1; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FKHRL1;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CAVEOLIN 1; CELL LINE, TUMOR; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; METFORMIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84856528344     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.11-192088     Document Type: Article

References (57)

1. Alexander, G. C., Sehgal, N. L., Moloney, R. M., and Stafford, R. S. (2008) National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch. Intern. Med. 168, 2088-2094
2. Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., and Gerich, J. E. (1995) Metabolic effects of metformin in non-insulindependent diabetes mellitus. N. Engl. J. Med. 333, 550-554
3. Bailey, C. J., and Turner, R. C. (1996) Metformin. N. Engl. J. Med. 334, 574-579 (Pubitemid 126537875)
4. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., and Morris, A. D. (2005) Metformin and reduced risk of cancer in diabetic patients. Brit. Med. J. 330, 1304-1305 (Pubitemid 40813563)
5. Bowker, S. L., Majumdar, S. R., Veugelers, P., and Johnson, J. A. (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29, 254-258 (Pubitemid 44106500)
6. Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J. F., and Bost, F. (2010) Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol. Cancer Ther. 9, 1092-1099
7. Rocha, G. Z., Dias, M. M., Ropelle, E. R., Osorio-Costa, F., Rossato, F. A., Vercesi, A. E., Saad, M. J., and Carvalheira, J. B. (2011) Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin. Cancer Res. 17, 3993-4005
8. Reitman, M. L., and Schadt, E. E. (2007) Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J. Clin. Invest. 117, 1226-1229 (Pubitemid 46718410)
9. Moreno-Navarrete, J. M., Ortega, F. J., Rodriguez-Hermosa, J. I., Sabater, M., Pardo, G., Ricart, W., and Fernandez-Real, J. M. (2011) OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes 60, 168-176
10. Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., Depinho, R. A., Montminy, M., and Cantley, L. C. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642-1646 (Pubitemid 41780780)
11. Miller, R. A., and Birnbaum, M. J. (2010) An energetic tale of AMPK-independent effects of metformin. J. Clin. Invest. 120, 2267-2270
12. Viollet, B., Guigas, B., Leclerc, J., Hebrard, S., Lantier, L., Mounier, R., Andreelli, F., and Foretz, M. (2009) AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol. (Oxf.) 196, 81-98
13. Foretz, M., Hebrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., and Viollet, B. (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120, 2355-2369
14. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (Pubitemid 32995375)
15. Cohen, A. W., Schubert, W., Brasaemle, D. L., Scherer, P. E., and Lisanti, M. P. (2005) Caveolin-1 expression is essential for proper nonshivering thermogenesis in brown adipose tissue. Diabetes 54, 679-686 (Pubitemid 40326265)
16. Levine, Y. C., Li, G. K., and Michel, T. (2007) Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK → Rac1 → Akt → endothelial nitric-oxide synthase pathway. J. Biol. Chem. 282, 20351-20364 (Pubitemid 47100039)
17. Salani, B., Briatore, L., Garibaldi, S., Cordera, R., and Maggi, D. (2008) Caveolin-1 down-regulation inhibits insulin-like growth factor-I receptor signal transduction in H9C2 rat cardiomyoblasts. Endocrinology 149, 461-465 (Pubitemid 351159315)
18. Salani, B., Passalacqua, M., Maffioli, S., Briatore, L., Hamoudane, M., Contini, P., Cordera, R., and Maggi, D. (2010) IGF-IR internalizes with caveolin-1 and PTRF/Cavin in HaCat cells. PLoS One 5, e14157
19. Pollak, M. (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-928
20. Li, D. (2011) Metformin as an antitumor agent in cancer prevention and treatment. J. Diabetes 10, 649-657
21. Hartog, H., Wesseling, J., Boezen, H. M., and van der Graaf, W. T. (2007) The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur. J. Cancer 43, 1895-1904 (Pubitemid 47284866)
22. Samani, A. A., Yakar, S., LeRoith, D., and Brodt, P. (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 28, 20-47 (Pubitemid 46220849)
23. Gallagher, E. J., and LeRoith, D. (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol. Metab. 21, 610-618
24. Linnerth, N. M., Siwicky, M. D., Campbell, C. I., Watson, K. L., Petrik, J. J., Whitsett, J. A., and Moorehead, R. A. (2009) Type I insulin-like growth factor receptor induces pulmonary tumorigenesis. Neoplasia 11, 672-682
25. Kikuchi, R., Sonobe, M., Kobayashi, M., Ishikawa, M., Kitamura, J., Nakayama, E., Menju, T., Miyahara, R., Huang, C. L., and Date, H. (2011) Expression of IGF1R is associated with tumor differentiation and survival in patients with lung adenocarcinoma. [E-pub ahead of print] Ann. Surg. Oncol. doi: 10.1245/s10434-011-1878-x
26. Gualberto, A., Dolled-Filhart, M., Gustavson, M., Christiansen, J., Wang, Y. F., Hixon, M. L., Reynolds, J., McDonald, S., Ang, A., Rimm, D. L., Langer, C. J., Blakely, J., Garland, L., Paz-Ares, L. G., Karp, D. D., and Lee, A. V. (2010) Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin. Cancer Res. 16, 4654-4665
27. Pal, S. K., Figlin, R. A., and Reckamp, K. (2010) Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol. Cancer Ther. 9, 1931-1944
28. Iwasa, T., Okamoto, I., Suzuki, M., Hatashita, E., Yamada, Y., Fukuoka, M., Ono, K., and Nakagawa, K. (2009) Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin. Cancer Res. 15, 5117-5125
29. Brodt, P., Samani, A., and Navab, R. (2000) Inhibition of the type I insulin-like growth factor receptor expression: novel strategies for antimetastatic therapy. Biochem. Pharmacol. 60, 1101-1107
30. Carboni, J. M., Wittman, M., Yang, Z., Lee, F., Greer, A., Hurlburt, W., Hillerman, S., Cao, C., Cantor, G. H., Dell-John, J., Chen, C., Discenza, L., Menard, K., Li, A., Trainor, G., Vyas, D., Kramer, R., Attar, R. M., and Gottardis, M. M. (2009) BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 8, 3341-3349
31. Casa, A. J., Dearth, R. K., Litzenburger, B. C., Lee, A. V., and Cui, X. (2008) The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front. Biosci. 13, 3273-3287 (Pubitemid 351594682)
32. Huang, H., and Tindall, D. J. (2007) Dynamic FoxO transcription factors. J. Cell Sci. 120, 2479-2487 (Pubitemid 47323857)
33. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868 (Pubitemid 29165088)
34. Yang, J. Y., and Hung, M. C. (2009) A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin. Cancer Res. 15, 752-757
35. Memmott, R. M., Mercado, J. R., Maier, C. R., Kawabata, S., Fox, S. D., and Dennis, P. A. (2010) Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev. Res. (Phila.) 3, 1066-1076
36. Barzu, O., and Michelson, S. (1983) Simple and fast purification of Escherichia coli adenylate kinase. FEBS Lett. 153, 280-284 (Pubitemid 13114014)
37. Kornberg, A., and Pricer, W. E., Jr. (1951) Enzymatic phosphorylation of adenosine and 2,6-diaminopurine riboside. J. Biol. Chem. 193, 481-495
38. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254
39. Orlichenko, L., Huang, B., Krueger, E., and McNiven, M. A. (2006) Epithelial growth factor-induced phosphorylation of caveolin 1 at tyrosine 14 stimulates caveolae formation in epithelial cells. J. Biol. Chem. 281, 4570-4579 (Pubitemid 43847715)
40. Raposio, E., Guida, C., Coradeghini, R., Scanarotti, C., Parodi, A., Baldelli, I., Fiocca, R., and Santi, P. L. (2008) In vitro polydeoxyribonucleotide effects on human pre-adipocytes. Cell Prolif. 41, 739-754
41. Herbst, R. S., Heymach, J. V., and Lippman, S. M. (2008) Lung cancer. N. Engl. J. Med. 359, 1367-1380
42. Drab, M., Verkade, P., Elger, M., Kasper, M., Lohn, M., Lauterbach, B., Menne, J., Lindschau, C., Mende, F., Luft, F. C., Schedl, A., Haller, H., and Kurzchalia, T. V. (2001) Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293, 2449-2452 (Pubitemid 32917325)
43. Razani, B., Engelman, J. A., Wang, X. B., Schubert, W., Zhang, X. L., Marks, C. B., Macaluso, F., Russell, R. G., Li, M., Pestell, R. G., Di Vizio, D., Hou, H., Jr., Kneitz, B., Lagaud, G., Christ, G. J., Edelmann, W., and Lisanti, M. P. (2001) Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276, 38121-38138
44. Bosch, M., Mari, M., Herms, A., Fernandez, A., Fajardo, A., Kassan, A., Giralt, A., Colell, A., Balgoma, D., Barbero, E., Gonzalez-Moreno, E., Matias, N., Tebar, F., Balsinde, J., Camps, M., Enrich, C., Gross, S. P., Garcia-Ruiz, C., Perez-Navarro, E., Fernandez-Checa, J. C., and Pol, A. (2011) Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility. Curr. Biol. 21, 681-686
45. El-Mir, M. Y., Nogueira, V., Fontaine, E., Averet, N., Rigoulet, M., and Leverve, X. (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223-228 (Pubitemid 30038975)
46. Onozato, R., Kosaka, T., Achiwa, H., Kuwano, H., Takahashi, T., Yatabe, Y., and Mitsudomi, T. (2007) LKB1 gene mutations in Japanese lung cancer patients. Cancer Sci. 98, 1747-1751 (Pubitemid 47487911)
47. Zakikhani, M., Blouin, M. J., Piura, E., and Pollak, M. N. (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res. Treat. 123, 271-279
48. Shukla, S., Shukla, M., Maclennan, G. T., Fu, P., and Gupta, S. (2009) Deregulation of FOXO3A during prostate cancer progression. Int. J. Oncol. 34, 1613-1620
49. Burgering, B. M., and Kops, G. J. (2002) Cell cycle and death control: long live Forkheads. Trends Biochem. Sci. 27, 352-360 (Pubitemid 34756518)
50. Fang, L., Wang, H., Zhou, L., and Yu, D. (2011) FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells. Toxicol. Appl. Pharmacol. 251, 8-15
51. Sunters, A., Madureira, P. A., Pomeranz, K. M., Aubert, M., Brosens, J. J., Cook, S. J., Burgering, B. M., Coombes, R. C., and Lam, E. W. (2006) Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res. 66, 212-220 (Pubitemid 43166027)
52. Liu, B., Fan, Z., Edgerton, S. M., Deng, X. S., Alimova, I. N., Lind, S. E., and Thor, A. D. (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8, 2031-2040
53. Zhuang, Y., and Miskimins, W. K. (2008) Cell cycle arrest in metformin-treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J. Mol. Signal. 3, 18
54. Roussel, E., Belanger, M. M., and Couet, J. (2004) G2/M blockade by paclitaxel induces caveolin-1 expression in A549 lung cancer cells: caveolin-1 as a marker of cytotoxicity. Anticancer Drugs 15, 961-967 (Pubitemid 39557483)
55. van den Heuvel, A. P., Schulze, A., and Burgering, B. M. (2005) Direct control of caveolin-1 expression by FOXO transcription factors. Biochem. J. 385, 795-802 (Pubitemid 40208841)
56. Alimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., and Thor, A. D. (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8, 909-915
57. Rattan, R., Giri, S., Singh, A. K., and Singh, I. (2005) 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem. 280, 39582-39593 (Pubitemid 41713917)